	Application No.	Applicant(s)
		CASHMAN ET AL.
Notice of Allowability	09/583,310 <b>Examiner</b>	Art Unit
	David J Steadman	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>amendment filed 12/16/03</u> .		
2. The allowed claim(s) is/are 4,5,38 and 40.		
3. The drawings filed on are accepted by the Examiner.		
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> </ul>		
1. Certified copies of the priority documents have been received.		
2.  Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.		
(a) The translation of the foreign language provisional application has been received.		
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
7. X A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
<ul> <li>8. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.</li> <li>(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached</li> <li>1) ☐ hereto or 2) ☐ to Paper No</li> </ul>		
(b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Examiner.		
(c) 🗌 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).		
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1 Notice of References Cited (PTO-892)	5 Notice of Informal	Patent Application (PTO-152)
2 Notice of Draftperson's Patent Drawing Review (PTO-948)		y (PTO-413), Paper No
3 Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No	B), 7☐ Examiner's Amen	dment/Comment
4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8⊠ Examiner's Stater 9⊡ Other	nent of Reasons for Allowance
- -	<del></del>	

Application/Control Number: 09/583,310

Art Unit: 1652

## **DETAILED ACTION**

## Status of the Application

- [1] A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 16, 2003 has been entered.
- [2] Claims 4-5, 38, and 40 are pending in the application.
- [3] Applicants' amendment to the claims filed December 16, 2003, is acknowledged. This listing of the claims replaces all previous listings and versions of the claims.
- [4] Applicants' arguments in the amendment filed December 16, 2003 have been fully considered and are deemed to be persuasive to overcome the rejections previously applied.

## Oath/Declaration

- [5] The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02. The oath or declaration is defective because: No date is provided under the signature of Applicant N. Lomri.
- [6] Applicant is now required to submit a substitute declaration or oath to correct the deficiencies set forth above. The substitute oath or declaration must be filed within the

Application/Control Number: 09/583,310

Art Unit: 1652

THREE MONTH shortened statutory period set for reply in the "Notice of Allowability" (PTO-37). Extensions of time may NOT be obtained under the provisions of 37 CFR 1.136. Failure to timely file the substitute declaration (or oath) will result in **ABANDONMENT** of the application. The transmittal letter accompanying the declaration (or oath) should indicate the date of the "Notice of Allowance" (PTOL-85) and the application number in the upper right hand corner.

## Reasons for Allowance

- The following is an Examiner's statement of reasons for allowance. While DNA sequences encoding adult human liver flavin-containing monooxygenases are known in the prior art (see reference AA of the IDS filed February 27, 2001), the examiner has found no teaching or suggestion in the prior art directed to an isolated DNA having the nucleotide sequence of SEQ ID NO:5 or 7. Therefore, claims 4-5, 38, and 40, directed to an isolated DNA encoding an adult human liver flavin-containing monooxygenase, wherein the DNA has the nucleotide sequence of SEQ ID NO:5 or 7 and a host cell comprising said DNA as encompassed by the claims, are allowable over the prior art of record.
- [8] Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Steadman, whose telephone number is (703)

Art Unit: 1652

308-3934. The Examiner can normally be reached Monday-Friday from 7:00 am to 5:30 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703) 308-3804. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Art Unit receptionist whose telephone number is (703) 308-0196.

David J. Steadman, Ph.D. Patent Examiner Art Unit 1652

REBECCA E. PROUTY PRIMARY EXAMINER

GROUP-1800